تعزيز نشاط الخلايا الجذعية يمكن أن يعزز فوائد العلاج المناعي

تمت إعادة برمجة الخلايا التائية في الجهاز المناعي إلى ذاكرة تشبه الخلايا الجذعية المتجددة (TSCM) الخلايا التي تعيش لفترة طويلة, نشطة للغاية “خلايا مناعية فائقة” مع نشاط مضاد للورم قوي, وفقا لبحث جديد أجراه مركز جورج تاون لومباردي الشامل للسرطان.

The reprogramming involves a novel approach the researchers developed that inhibits the activity of proteins known as MEK1/2. حالياً, several MEK inhibitors are used to effectively treat melanoma, but this study demonstrates that MEK inhibitors don’t just target certain types of cancer cells, but rather, more broadly, reprogram T cells to fight many types of cancer.

The finding appears November 23, 2020, فيNature Immunology.

“Although immunotherapies have improved survival for cancer patients over recent years, survival rates remain sub-optimal. لذلك, there is an urgent need to develop novel, more effective anti-cancer immunotherapies,” says Samir N. Khleif, دكتوراه في الطب, director of The Jeannie and Tony Loop Immuno-Oncology Laboratory and head of the team that conducted this research. “Our research shows that using drugs that have already been approved for human use may significantly enhance currently available immune therapeutic approaches, thereby leading to better and more durable anti-cancer responses.”